Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 21, 2026, titled "Glenmark Pharmaceuticals Launches GLIPIQ (Semaglutide) In India. Setting a new benchmark in affordability for GLP-1 therapy, with weekly treatment starting at Rs. 325".